| Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in developing product candidates to address a range of inflammatory diseases. Co.'s primary product candidate is VTX958, an oral, selective allosteric tyrosine kinase type 2 (TYK2) inhibitor. VTX958 is designed to selectively inhibit TYK2 without detectable inhibition of other Janus kinase isoforms. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for the treatment of ulcerative colitis. Co. is also developing a portfolio of differentiated NOD-like receptor protein 3 (NLRP3) inhibitors to address several indications driven by NLRP3 inflammasome activation. The VTYX YTD return is shown above.
The YTD Return on the VTYX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VTYX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VTYX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.